Johnson and Johnson to Acquire V-Wave, Expanding and Strengthening J&J MedTech Segment
Shots:
- J&J entered into a definitive agreement to acquire V-Wave for an upfront of $600M, and approx. $1.1B regulatory and commercial milestones. The acquisition will be concluded in H2’24
- Under US GAAP, this transaction will be treated as an asset acquisition, leading to a non-tax deductible in-process R&D charge of about $600M at closure. J&J projects a diluted adjusted EPS impact of roughly $0.24 in 2024 and $0.06 in 2025. The full-year financial outlook will be presented in Q3’24 results
- The acquisition will make V-wave a part of J&J’s Medtech segment in the cardiovascular area
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News: Johnson & Johnson’s Darzalex Faspro Quadruplet Combination Gains the US FDA’s Approval to Treat Multiple Myeloma (MM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
